Collegium Pharmaceutical (COLL) Total Non-Current Liabilities (2014 - 2025)

Collegium Pharmaceutical's Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $1.4 billion for Q4 2025.

• In Q4 2025, Total Non-Current Liabilities fell 5.47% year-over-year to $1.4 billion; the TTM figure through Dec 2025 stood at $1.4 billion (down 5.47% YoY), while the FY2025 annual figure was $1.4 billion, down 5.47% from the prior year.
• Total Non-Current Liabilities was $1.4 billion for Q4 2025 at Collegium Pharmaceutical, up from $1.3 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $1.4 billion in Q4 2024 to a low of $947.9 million in Q4 2023.
• Historically, Total Non-Current Liabilities has averaged $1.3 billion across 3 years, with a median of $1.4 billion in 2025.
• The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities soared 51.24% in 2024, then declined 5.47% in 2025.
• A 3-year view of Total Non-Current Liabilities shows it stood at $947.9 million in 2023, then jumped by 51.24% to $1.4 billion in 2024, then declined by 5.47% to $1.4 billion in 2025.
• The last three Total Non-Current Liabilities figures came in at $1.4 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.4 billion (Q2 2025), per Business Quant data.